Participated · Equity · Feb 2026

Xyall BV is a molecular pathology technology company focused on automating the labor-intensive step of tissue dissection prior to PCR and next-generation sequencing analyses. Its flagship product, the Tissector TableTop, integrates high-resolution slide imaging, precise image registration, workflow software, and robotics to deliver fully automated, contamination-free tissue selection. Introduced in 2023, the system is already installed in more than 15 Tier-1 commercial, academic, pharmaceutical, and research labs, including sites in the United States. Customers adopt the platform to cope with staffing shortages and the demand for faster, more precise oncology diagnostics. By bridging morphological assessment and molecular diagnostics, Xyall positions itself as a critical enabler of personalized medicine. The company plans to use new capital to accelerate its global rollout and deepen penetration of both research and clinical laboratories. Its recent €7.6 million raise strengthens its balance sheet for these expansion efforts.

Participated · Series A · May 2019

Headquartered in Liège, Belgium, SamanTree Medical is a privately held med-tech firm focused on improving oncologic surgery through its Histolog® Scanner, the first device to use massively parallel confocal microscopy for intra-operative imaging. The system captures nearly 30,000 images simultaneously, generating histology-like views in about one minute without damaging the specimen. To date, the technology has been used on more than 6,000 patients and has demonstrated a 67 % reduction in re-operation rates for breast-conserving surgery, while offering sensitivity of 73 %–91 % and specificity of 91 %–100 % compared with conventional pathology. In prostatectomies, Histolog images can be obtained in 5–20 minutes versus 45–60 minutes for frozen-section analysis, enabling more nerve-sparing procedures. The company plans to accelerate R&D, further develop the scanner, and scale commercialization across Europe and the United States. Its growth strategy is now supported by a €20 million venture-debt facility from the European Investment Bank (EIB), bolstering its financial resources for expansion.